Analyst firms · Barclays · CYTK

Barclays CYTK price target and rating history

Cytokinetics Incorporated (CYTK) · Health Care

Barclays rates Cytokinetics Incorporated (CYTK) Overweight with a $87 price target, as of its latest action on Jan 28, 2026. It has published 3 rating actions on CYTK since July 2021, including 0 upgrades and 0 downgrades. Across 5 firms with a CYTK price target in the last 12 months, the median target is $95. Barclays's $87 is 8% below that.

Current rating
Overweight
Price target
$87
Median target, all firms
$95
Actions on CYTK
3

Barclays price target on CYTK

$87$64$4020222023202420252026
Barclays price target on CYTK, each point a stated target, July 2021 to January 2026.

Every Barclays rating on CYTK

How other firms rate CYTK

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
UBSBuy$115Jun 29, 2026
CitigroupBuy$99May 19, 2026
Wells FargoOverweight$95Apr 10, 2026
BarclaysOverweight$87Jan 28, 2026
Goldman SachsBuy$95Dec 18, 2025

Questions about Barclays and CYTK

What is Barclays's price target for CYTK?
Barclays's latest stated price target for Cytokinetics Incorporated (CYTK) is $87, from its action on Jan 28, 2026.
What is Barclays's rating on CYTK?
Barclays rates CYTK Overweight, a bullish rating, as of Jan 28, 2026.
When did Barclays last change its view on CYTK?
On Jan 28, 2026, Barclays resumes coverage at Overweight, price target $87.
How does Barclays's CYTK target compare with other analysts?
Across 5 firms with a CYTK price target in the last 12 months, the median target is $95. Barclays's $87 is 8% below that.

More CYTK rating histories

All Barclays ratingsCYTK news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.